Anugraha Narayana Das (IDAS) takes charge as Controller General of Defence Accounts 
Defence Watch

Anugraha Narayana Das (IDAS) takes charge as Controller General of Defence Accounts

Anugraha Narayana Das (IDAS) has assumed charge as the Controller General of Defence Accounts (CGDA) on Friday

Defence Watch Bureau

New Delhi: Anugraha Narayana Das (IDAS) has assumed charge as the Controller General of Defence Accounts (CGDA) with effect from May 1. Prior to this, he was serving as Additional Controller General of Defence Accounts.

Follow The PSUWatch Channel on WhatsApp

A 1991-batch officer of the Indian Defence Accounts Service (IDAS), Das brings over three decades of experience in defence financial management and public administration.

An alumnus of Utkal University and ICPE University of Ljubljana, he has led several key initiatives in procurement policy, audit and oversight, budgeting and expenditure monitoring. His professional training includes programmes at premier institutions such as Indian Institute of Management Bangalore and Duke University.

Follow PSU Watch on LinkedIN

Over the course of his career, Das has held important positions across the Ministry of Defence, Service Headquarters and field formations. His key assignments include Director in the Ministry of Water Resources, Additional Financial Adviser and Joint Secretary in the Ministry of Defence, Principal Integrated Financial Adviser at Army Headquarters, and Special Controller General of Defence Accounts at CGDA Headquarters.

(PSU Watch– India's Business News centre that places the spotlight on PSUs, Bureaucracy, Defence and Public Policy is now on Google News. Click here to follow. Also, join PSU Watch Channel in your Telegram. You may also follow us on Twitter here and stay updated.)

Power Secretary reviews SJVN hydro projects in Himachal

MDL delivers 6th Nilgiri-class stealth frigate ‘Mahendragiri’ to Indian Navy

RBI says 98.47% of Rs 2,000 banknotes returned

NHAI launches India’s first barrier-less MLFF tolling system

India supplies 20% of global generic medicines; its IP rules WTO-compliant: GTRI